Table 1 Clinicopathological characteristics of CCA patients
Code | Location | Age | Gender | Size (cm) | Hepatitis | CA 19-9 (U/ml) | Differentiation | Stage (TNM) |
|---|---|---|---|---|---|---|---|---|
T1 | E | 60 | F | 2.5 | HBV−; HCV− | 3154 | M | T3N0M0 |
T2 | E | 47 | F | 4.0 | HBV+; HCV− | 82.9 | W | T2N1M0 |
T3 | E | 76 | M | 4.6 | HBV−; HCV− | 32 394 | W | T?N0M0 |
T4 | I | 63 | F | 2.4 | HBV−; HCV− | 55.9 | W | T2N1M0 |
T5a | E | 33 | F | 4.0 | HBV−; HCV− | 3.2 | M-P | T4N1M0 |
T6 | NA | 71 | F | 5.0 | HBV−; HCV− | 2518 | P | T3N1M0 |
T7a | I | 50 | M | 5.0 | HBV+; HCV− | 2098.3 | W | T3N0M0 |
T8a | I | 62 | M | 10.0 | HBV+; HCV− | 14 047.5 | M-P | T3N1M0 |
T9 | E | 73 | M | 4.0 | HBV−; HCV− | 164.1 | M | T1N0M0 |
T10 | I | 71 | F | 7.9 | HBV−; HCV− | 68.2 | M-P | T1N0M0 |
T11 | I | 56 | M | 5.0 | HBV+; HCV− | 145.9 | M | T4N?M0 |
T12 | E | 63 | F | 3.0 | HBV−; HCV− | 2041 | P | T3N1M0 |
T13a | I | 59 | M | 7.0 | HBV+; HCV− | 18 706 | M-P | T3N1M0 |
T14 | E | 50 | M | 1.5 | HBV−; HCV− | 158.8 | W | T2N0M0 |
T15a | I | 45 | F | 8.5 | HBV−; HCV− | 17 929.9 | W | T3N0M0 |
T16 | NA | 49 | M | 1.5 | HBV−; HCV− | 946 | M | T?N1M0 |
T17a | E | 86 | M | 2.0 | HBV−; HCV− | 46.3 | W | T?N0M0 |
T18 | E | 57 | M | 3.8 | HBV−; HCV− | 160.6 | W | T4N1M0 |
T19 | E | 46 | M | 1.2 | HBV−; HCV− | NA | W | T2N0M0 |
T20 | I | 62 | F | 3.0 | HBV−; HCV− | 1922.2 | M | T2N1M0 |
T21 | E | 61 | M | 3.5 | HBV+; HCV− | 0.9 | W | T3N1M0 |
T22 | I | 66 | M | 5.0 | HBV−; HCV− | 0 | W | T3N1M0 |
T23 | E | 67 | M | 2.5 | HBV−; HCV− | 606.4 | M-P | T3N1M0 |
T24 | E | 62 | M | 2.7 | HBV−; HCV− | 29.5 | M | T4N0M0 |
